In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

Time really does fly. And when you look back at 2025, we’re sure you’ve collected a mix of moments: some joyful, some ...

Knowable Magazine reports 2025 faced turmoil in U.S. science amid job cuts and budget slashes, yet saw advances in gene ...

Time really does fly. And when you look back at 2025, we’re sure you’ve collected a mix of moments: some joyful, some ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

Rapid advances in sequencing technologies have transformed our ability to diagnose human genetic disorders, yet many patients still lack a molecular ...

Researchers are edging closer to something long imagined but never quite within reach: a single vaccine platform that could ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Earlier this week, Thermo Fisher Scientific reported the first patient enrollment in its new international PPD CorEvitas Alzheimer’s Disease Registry and introduced next-generation Gibco Bacto CD ...

Osorio, I. , Olson, D. and Aryana, K. (2025) Acid and Heat Mild Stresses Improve the Overall Heat Tolerance of Leuconostoc ...

mRNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the blueprint for functional proteins in the body and induces therapeutic effects.

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...